

Resource Summary Report

Generated by [dkNET](#) on Aug 2, 2026

Alexa Fluor(R) 488 anti-mouse CD3

RRID:AB_389301

Type: Antibody

Proper Citation

BioLegend Cat# 100210, RRID:AB_389301

Antibody Information

URL: http://antibodyregistry.org/AB_389301

Proper Citation: BioLegend Cat# 100210, RRID:AB_389301

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, IHC-F, 3D IHC

Antibody Name: Alexa Fluor(R) 488 anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_389301

Vendor: BioLegend

Catalog Number: 100210

Alternative Catalog Numbers: 100212

Record Creation Time: 20250819T214038+0000

Record Last Update: 20250819T234415+0000

Ratings and Alerts

No rating or validation information has been found for Alexa Fluor(R) 488 anti-mouse CD3.

No alerts have been found for Alexa Fluor(R) 488 anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Benmebarek MR, et al. (2025) Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME. *Immunity*, 58(4), 926.

Gomez AM, et al. (2025) Aberrant hypothalamic neuronal activity blunts glucocorticoid diurnal rhythms in murine breast cancer. *Neuron*.

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. *Cancer cell*, 43(2), 269.

Wang Y, et al. (2025) Cognate interaction-dependent pathogenicity of meningeal B cells drives neuroinflammation relapse. *Immunity*, 58(9), 2256.

Deng T, et al. (2025) CINTER-seq: Chemical profiling reveals interaction-dependent cell landscapes and gene signatures in vivo. *Immunity*, 58(9), 2336.

Li S, et al. (2025) Protocol for multiplex immunofluorescence imaging of mouse intestinal tumors. *STAR protocols*, 6(2), 103776.

Newsome RC, et al. (2025) Microbial-derived immunostimulatory small molecule augments anti-PD-1 therapy in lung cancer. *Cell reports. Medicine*, 102519.

You S, et al. (2024) Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity. *Cancer cell*, 42(8), 1415.

Zhang YC, et al. (2024) Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies. *Theranostics*, 14(16), 6249.

Zheng C, et al. (2024) IFN γ -induced BST2⁺ tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling. *Cell reports*, 43(4), 114088.

Andreata F, et al. (2024) Therapeutic potential of co-signaling receptor modulation in hepatitis B. *Cell*, 187(15), 4078.

Shehata L, et al. (2024) Interleukin-4 downregulates transcription factor BCL6 to promote memory B cell selection in germinal centers. *Immunity*.

First NJ, et al. (2023) *Bordetella* spp. block eosinophil recruitment to suppress the generation of early mucosal protection. *Cell reports*, 42(11), 113294.

Tibbs TN, et al. (2023) Mice with FVB-derived sequence on chromosome 17 succumb to disseminated virus infection due to aberrant NK cell and T cell responses. *iScience*, 26(11), 108348.

Maradana MR, et al. (2023) Dietary environmental factors shape the immune defense against *Cryptosporidium* infection. *Cell host & microbe*, 31(12), 2038.

Zhou X, et al. (2023) MHC class II regulation of CD8+ T cell tolerance and implications in autoimmunity and cancer immunotherapy. *Cell reports*, 42(11), 113452.

Aramburu IV, et al. (2022) Functional proteomic profiling links deficient DNA clearance with increased mortality in individuals with severe COVID-19 pneumonia. *Immunity*, 55(12), 2436.

Cautivo KM, et al. (2022) Interferon gamma constrains type 2 lymphocyte niche boundaries during mixed inflammation. *Immunity*, 55(2), 254.

Yeh CH, et al. (2022) Primary germinal center-resident T follicular helper cells are a physiologically distinct subset of CXCR5hiPD-1hi T follicular helper cells. *Immunity*, 55(2), 272.

Pylaeva E, et al. (2022) During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor-draining lymph nodes. *Cell reports*, 40(7), 111171.